Norway· NO-ID_DEBBF06F-3EA1-4452-9158-18D8A9159170
Zavicefta
A ceftazidim und beta-lactamase-inhibitor product containing ceftazidime + avibactam, registered in Norway by Pfizer Ireland Pharmaceuticals Unlimited Company. The same ATC class is registered in 10 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Ceftazidim und beta-lactamase-inhibitor is registered in 10 of 19 countries.
Countries holding a registration under ATC J01DD52 (ceftazidim und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Ceftazidim und beta-lactamase-inhibitor · ATC J01DD52
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of ceftazidim und beta-lactamase-inhibitor costs, country by country.
Normalised to the WHO defined daily dose (6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ceftazidim und beta-lactamase-inhibitor · price per daily dose (6 g)
USD · FX 28 Sept 2026
- CH Switzerland$407.92
The record
At a glance
FEST (Norway)- Active substance
- Ceftazidime + Avibactam
- Manufacturer
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Country
- Norway (NO)
- ATC code
- J01DD52
- ATC class
- Ceftazidim und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_DEBBF06F-3EA1-4452-9158-18D8A9159170
- no_varenummer18313310NOK 13422
- gtin5415062315064
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftazidim und beta-lactamase-inhibitor in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandZaviceftaOrifarm Oy
- SpainZAVICEFTA 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Ireland Pharmaceuticals Unlimited Company
- United StatesAVYCAZAllergan, Inc.
- United KingdomZavicefta 2g/0.5g powder for concentrate for solution for infusion vialsPfizer Ltd
- SwitzerlandZavicefta, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungPfizer AG
- IcelandZaviceftaPfizer Ireland Pharmaceuticals
- NetherlandsZAVICEFTA 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusiePfizer Ireland Pharmaceuticals, Operations Services Group
- PolandZaviceftaPfizer Ireland Pharmaceuticals
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Zavicefta
- Liechtenstein · Zavicefta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4ab770ab-9cce-471e-8fa4-4590a91730c0 GET /v1/drugs/4ab770ab-9cce-471e-8fa4-4590a91730c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Ceftazidim og beta-laktamasehemmer",
"merkevare_id": "ID_DEBBF06F-3EA1-4452-9158-18D8A9159170",
"name_form_strength": "Zavicefta pulv til kons til inf væske, oppl 2000 mg/500 mg",
"prescription_group": "C"
}See everything about ceftazidim und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.